Why Innovation and Quality Stocks Can Potentially Thrive in a Higher-Rate World
But the second time frame in Figure 1, one that encompasses the end of the low-rate era, tells a different story. Following a series of interest-rate increases by major central banks, business financing costs are meaningfully higher. Today’s higher-rate environment has punished vulnerable businesses with weaker balance sheets. The differential between companies with positive and negative earnings has widened significantly since the Fed began its rate-raising campaign in 2021.
Not all earners and non-earners are created equal, however. While it may seem like holding a portfolio of earners, and avoiding non-earners, is a winning formula, we believe a more active approach is prudent. Seeking out companies with positive earnings should be complemented by an assessment of relative value, i.e., whether a stock is too expensive versus comparable equities, as well as an assessment of a company’s ability to generate stable or growing free cash flows.
We should look at non-earners with a similar level of scrutiny. Not all non-earning companies are bad from an investment standpoint. In fact, those companies prioritizing investing back in their businesses in the form of research and development (R&D), at the expense of current earnings, historically have outperformed those who spent at lower levels. We have found that the highest R&D intensity companies—those that spend the most on R&D relative to revenues—historically have superior revenue growth, earnings growth, and long-term performance versus the broader market.1
While companies taking advantage of unprecedented technological innovation in areas like biotechnology and artificial intelligence (AI) are growing substantially faster than the broader market and offer the potential for outsized returns, the new higher-rate regime also necessitates a focus on quality, in our view—seeking out companies with higher-return metrics and lower leverage.
Furthermore, an equal blend of innovation (as defined by top decile R&D intensity companies), free cash flow yield, and quality (as defined by top-decile return on equity, return on assets, return on invested capital, and a bottom 50% standing in terms of debt/equity leverage), over a long period of time has been a winning combination, outperforming the MSCI All Country World Index (Figure 2). This combination has historically made for a portfolio well suited to different interest-rate and economic environments.